Targeting CD39 in combination with IL-2/anti-IL-2 complexes enhances cytotoxic immunity and limits tumor progression.
Abrate, Carolina, Valentina Brunotto, Sabrina N Bossio, Santiago Boccardo, Jimena Tosello Boari, Pamela Caudana, Lara Hernandez, et al. 2026. “Targeting CD39 in Combination With IL-2/Anti-IL-2 Complexes Enhances Cytotoxic Immunity and Limits Tumor Progression.”. Frontiers in Immunology 17: 1730342.